US4342756A - Aminocyclopentane alkenoic acids and esters and pharmaceutical compositions - Google Patents

Aminocyclopentane alkenoic acids and esters and pharmaceutical compositions Download PDF

Info

Publication number
US4342756A
US4342756A US06/258,721 US25872181A US4342756A US 4342756 A US4342756 A US 4342756A US 25872181 A US25872181 A US 25872181A US 4342756 A US4342756 A US 4342756A
Authority
US
United States
Prior art keywords
methoxy
alkyl
biphenyl
phenyl
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US06/258,721
Other languages
English (en)
Inventor
Eric W. Collington
Peter Hallett
Christopher J. Wallis
John Bradshaw
Norman F. Hayes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Assigned to GLAXO GROUP LIMITED reassignment GLAXO GROUP LIMITED ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BRADSHAW, JOHN, COLLINGTON, ERIC W., HALLETT, PETER, HAYES, NORMAN, WALLIS, CHRISTOPHER J.
Application granted granted Critical
Publication of US4342756A publication Critical patent/US4342756A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C17/00—Preparation of halogenated hydrocarbons
    • C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
    • C07C17/16—Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0033—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/27—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation
    • C07C45/30—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation with halogen containing compounds, e.g. hypohalogenation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/112—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935—Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/12—Radicals substituted by halogen atoms or nitro or nitroso radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
    • D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
    • D01F6/58—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products
    • D01F6/62—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products from polyesters
    • D01F6/625—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products from polyesters derived from hydroxy-carboxylic acids, e.g. lactones

Definitions

  • prostaglandins G 2 and H 2 , and thromboxane A 2 are naturally occurring, reactive metabolites of arachidonic acid in human platelets. They are not only potent aggregatory agents but are also constrictors of vascular and bronchial smooth muscle, and therefore substances which antagonise their effects are of considerable interest in human medicine.
  • the invention thus provides compounds of the general formula (1) ##STR2## wherein X is cis or trans --CH ⁇ CH--;
  • R 1 is straight or branched C 1-7 alkyl bearing as a terminal substituent --COOR 3 where R 3 is a hydrogen atom, C 1-6 alkyl or C 7-10 aralkyl (e.g. benzyl);
  • Y represents a saturated heterocyclic amino group which has 5-8 ring members and (a) optionally contains in the ring --O--, --S--, --SO 2 --, --NR 4 (where R 4 is a hydrogen atom, C 1-7 alkyl or aralkyl having a C 1-4 alkyl portion); and/or (b) is optionally substituted by one or more C 1-4 alkyl groups;
  • R 2 is (i) C 2-4 alkanoyl; (ii) C 3-6 alkenyl, optionally substituted by phenyl (the phenyl being optionally substituted by C 1-4 alkyl, C 1-4 alkoxy, halogen, C 5-7 cycloalkyl or phenyl (C 1-4 ) alkyl), biphenyl (optionally substituted by C 1-4 alkyl, C 1-4 alkoxy or halogen), or naphthyl; (iii) C 1-12 alkyl; (iv) C 1-5 alkyl substituted by (a) phenyl [optionally substituted by halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy, C 1-4 hydroxyalkoxy, trifluoromethyl, cyano, aryloxy (e.g.
  • phenoxy C 5-7 cycloalkyl, aralkoxy (e.g. benzyloxy), dimethylaminomethyl, carboxamido (--CONH 2 ), thiocarboxamido (--CSNH 2 ), C 1-4 alkanoyl, --NR 5 R 6 (where R 5 and R 6 are the same or different and are each a hydrogen atom or C 1-4 alkyl, or where --NR 5 R 6 is a saturated heterocyclic amino group as defined above for Y), C 1-3 alkylthio, C 1-3 alkylsulphinyl, C 1-3 alkylsulphonyl, phenylalkyl having a C 1-3 alkyl portion, aminosulphonyl, C 1-3 alkanoylaminosulphonyl, phenylsulphonyl (the phenyl portion being optionally substituted by C 1-3 alkyl or C 1-3 alkoxy), nitro, or thienyl], (b) biphen
  • physiologically acceptable salts and the solvates e.g. hydrates thereof.
  • alkyl groups referred to above in the definition of the compounds of formula (1) may be straight or branched.
  • the alkyl portion of the group R 1 may for example contain 1-5 carbon atoms in a straight or branched chain, and is preferably --CH 2 CH 2 --.
  • suitable R 3 groups are C 1-3 alkyl (e.g. methyl), but R 3 is preferably a hydrogen atom.
  • R 1 is thus preferably --(CH 2 ) 2 COOH.
  • R 3 is a hydrogen atom
  • the compounds are capable of salt formation with bases and the compounds are preferably used in the form of such salts.
  • suitable salts are alkali metal (e.g. sodium and potassium), alkaline earth metal (e.g. calcium or magnesium), ammonium, substituted ammonium (e.g. tromethamine or dimethylaminoethanol), piperazine, N,N-dimethylpiperazine, morpholine, piperidine and tertiary amino (e.g. triethylamine) salts.
  • Inorganic salts are preferred.
  • X is preferably a cis --CH ⁇ CH-- group.
  • the heterocyclic amino group Y may for example have a 5, 6 or 7-membered ring, e.g. pyrrolidino, piperidino, morpholino, piperazino, thiamorpholino, 1-dioxothiamorpholino, homomorpholino and hexamethyleneimino.
  • pyrrolidino piperidino, morpholino, piperazino, thiamorpholino, 1-dioxothiamorpholino, homomorpholino and hexamethyleneimino.
  • the optional substituents which may be present on a second nitrogen atom in the ring are methyl, ethyl and benzyl.
  • the carbon atoms of the heterocylic rings may for example be substituted by methyl or ethyl.
  • Y is preferably piperidino, morpholino, homomorpholino, thiamorpholino or 1-dioxothiamorpholino, and compounds in which
  • the amino group Y enables the compounds to form salts with organic acids, e.g. maleates.
  • R 2 may for example be C 5-10 alkyl (e.g. pentyl or decyl); C 3-5 alkenyl (e.g. allyl, optionally substituted by phenyl); or C 1-5 alkyl (e.g. methyl or propyl) substituted by phenyl [optionally substituted by a C 1-4 alkyl (e.g. tert butyl), C 5-7 cycloalkyl (e.g. cyclohexyl), C 1-3 alkylthio (e.g. methylthio), phenyl (C 1-3 ) alkyl (e.g.
  • benzyl or thienyl
  • biphenyl [optionally substituted by C 1-3 alkyl (e.g. methyl), C 1-3 alkoxy (e.g. methoxy), halogen (e.g. chlorine) or phenyl], or naphthyl.
  • R 2 is preferably a phenylalkyl group in which the alkyl portion contains C 1-3 carbon atoms and the phenyl is substituted with one of the following groups: C 1-3 alkylthio, thienyl or phenyl optionally substituted by C 1-3 alkyl, C 1-3 alkoxy; halogen or phenyl; or cinnamyl.
  • R 2 groups are phenylalkyl groups in which the alkyl portion is a C 1-3 alkylene chain and the phenyl group carries a phenyl substituent, preferably in the para-position (which phenyl substituent is optionally substituted by a C 1-3 alkyl, C 1-3 alkoxy or halogen, this additional substituent preferably being in the meta or more particularly the para-position); or cinnamyl.
  • a particularly preferred group of compounds has the formula (1) in which:
  • X is cis --CH ⁇ CH--
  • R 1 is --CH 2 CH 2 COOH
  • Y is morpholino or piperidino
  • R 2 is phenyl (C 1-3 ) alkyl in which the phenyl group is substituted by phenyl (which phenyl substituent is optionally substituted by C 1-3 alkyl, C 1-3 alkoxy or halogen); or cinnamyl.
  • physiologically acceptable salts and solvates e.g. hydrates
  • Particularly important compounds in this latter group are those in which Y is morpholino and R 2 is 1,1'-biphenylmethyl; 1,1'-biphenylmethyl substituted in the para-position by methyl, methoxy or chloro or in the meta-position by methoxy; 1,1'-biphenylpropyl; or cinnamyl; and those in which Y is piperidino and R 2 is 1,1'-biphenylmethyl or 4'-methoxy-1,1'-biphenylmethyl.
  • Y is morpholino and R 2 is 1,1'-biphenylmethyl; 1,1'-biphenylmethyl substituted in the para-position by methyl, methoxy or chloro or in the meta-position by methoxy; 1,1'-biphenylpropyl; or cinnamyl
  • Y is piperidino and R 2 is 1,1'-biphenylmethyl or 4'-methoxy-1,1'-
  • Compounds of formula (1) inhibit blood platelet aggregation and bronchoconstriction.
  • the test for inhibition of platelet aggregation is as described by G. V. Born in Nature 194, 927-929 (1962) except in that collagen is used instead of ADP as the pro-aggregatory agent.
  • the test for potential inhibition of bronchoconstriction is as described by K. M. Lulich et al in British Journal of Pharmacology 58, 71-79, (1976) except guinea-pig lung is used instead of cat lung.
  • the compounds are thus of interest in the treatment of asthma, and as inhibitors of platelet aggregation and thrombosis for use in renal dialysis and the treatment and prevention of occlusive vascular diseases such as arteriosclerosis, atherosclerosis, peripheral vascular disease, cerebral vascular disease including transient ischaemic attacks, stroke, pulmonary embolism, diabetic, retinopathy, post operative thrombosis, angina and myocardial infarction. They may be formulated in conventional manner for use, with one or more pharmaceutical carriers.
  • the pharmaceutical composition may take the form of, for example, tablets, capsules, powders, solutions, syrups, or suspensions prepared by conventional means with acceptable excipients.
  • the compounds may be formulated for parenteral administration by bolus injections or continuous infusion.
  • Formulations for injections may be presented in unit dosage form in ampoules, or in multi-dose containers, which an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form for reconstitution before use with a suitable vehicle, e.g. sterile pyrogen-free water.
  • the compounds are conveniently delivered in the form of an aerosol spray presentation from pressurised packs or a nebuliser, or as a cartridge from which the powdered composition may be inhaled with the aid of a suitable device.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the compounds are preferably administered orally, for example in amounts of 0.05 to 10 mg/kg body weight, 1 to 4 times daily.
  • the compounds may also be administered orally in amounts of 0.05 to 10 mg/kg body weight, 1 to 4 times daily; preferably however they are administered by inhalation at doses varying from 0.3 to 30 mg, 1 to 4 times daily.
  • the compounds may be used in combination with other antiasthmatic agents.
  • Compounds of formula (1) may be prepared by oxidising a corresponding hydroxy compound, e.g. a compound of formula (2) ##STR3## (wherein R 1a is C 1-7 alkyl substituted by --COOR 3 , --CH 2 OH or --CHO).
  • Suitable methods of oxidation include using a Cr VI oxidising reagent in a suitable solvent, e.g. chromic acid in acetone (e.g. Jones reagent, preferably used in the presence of a diatomaceous silica such as Celite) or CrO 3 in pyridine. These reagents are for example used at temperatures of -20° to room temperature.
  • a suitable solvent e.g. chromic acid in acetone (e.g. Jones reagent, preferably used in the presence of a diatomaceous silica such as Celite) or CrO 3 in pyridine.
  • an activated sulphur reagent e.g. (i) N-chlorosuccinimidedimethylsulphide complex in a suitable solvent (e.g. toluene or dichloromethane) at temperatures of for example -25° to 25°, preferably at 0°-5°, (ii) a dialkylsulphoxide (e.g. dimethylsulphoxide) activated by a suitable electrophilic reagent (such as oxalyl chloride, acetyl bromide or thionyl chloride) in a suitable solvent (e.g. toluene or dichloromethane), e.g.
  • a suitable solvent e.g. toluene or dichloromethane
  • dicyclohexylcarbodiimide can also be used as the electrophilic reagent (preferably in the presence of CF 3 COOH or its pyridinium salt) at for example -10° to room temperature, using the same solvents, or (iii) pyridine --SO 3 complex in dimethylsulphoxide, preferably at 0° to room temperature.
  • R 3 is a hydrogen atom
  • better yields are sometimes obtained by prior protection of the carboxyl group, for example in the form of a trialkyl (e.g. trimethyl, triethyl or dimethyl(1,1-dimethylethyl))silyl ester.
  • a trialkyl e.g. trimethyl, triethyl or dimethyl(1,1-dimethylethyl)silyl ester.
  • Cr VI oxidising agents are generally preferred. The choice of oxidation method however will depend on the nature of the starting material of formula (2). Thus when R 1a is --CH 2 OH or --CHO, a Cr VI oxidising agent will generally be used. When Y is in the ⁇ -configuration conditions should be chosen to effect epimerisation, either at the same time or after oxidation.
  • Any hydroxy or amino group present in the starting material and required in the end product should be suitably protected in this reaction.
  • the acid may be converted into an activated derivative (e.g. a corresponding mixed anhydride) e.g. by reaction with an alkyl chloroformate (e.g. isobutyl chloroformate) in the presence of a suitable base, e.g. triethylamine or pyridine.
  • an activated derivative e.g. a corresponding mixed anhydride
  • an alkyl chloroformate e.g. isobutyl chloroformate
  • a suitable base e.g. triethylamine or pyridine.
  • the activated derivative can then be reacted with an appropriate alcohol, for example using a solvent such as acetone and temperatures of -10° to room temperature.
  • Compounds of formula (1) may also be prepared by selective reduction of a corresponding compound of formula (1) in which X is an acetylene group. These intermediates are also novel compounds. Suitable methods of reduction include using hydrogen in the presence of a catalyst, e.g. palladium on a support (e.g. CaCO 3 or BaSO 4 ) and poisoned for example by lead or pyridine Suitable solvents include ethyl acetate or methanol.
  • a catalyst e.g. palladium on a support (e.g. CaCO 3 or BaSO 4 )
  • Suitable solvents include ethyl acetate or methanol.
  • salts of compounds of formula (1) may be formed by conventional methods, for example by treating acids of formula (1) with appropriate bases. Salts may also be formed with acids.
  • the salts may be formed in conventional manner.
  • amine salts are conveniently prepared by adding the amine to a solution of an acid of formula (1) in a solvent such as ether.
  • Salts of inorganic bases may be prepared by adding the base to a solution of the acid in an aqueous organic solvent.
  • Certain salts may also be prepared by exchange of cation; for example, calcium salts may be prepared by addition of a calcium salt (e.g. the chloride or acetate) to a solution of a salt of a compound of formula (1), e.g. an amine or alkali metal salt.
  • reaction is particularly suitable for the preparation of compounds in which R 1 is terminally substituted by --COOH (in salt form).
  • Any hydroxy group present is preferably in a protected state prior to this reaction. Suitable hydroxyl protecting groups are described below. Any --NH 2 group present should also be protected, e.g. by t-butoxycarbonyl.
  • the configuration of the group X and R 1 and R 2 may then be modified to provide other compounds of formula (2) e.g. by methods (1)-(0) below or (b) or (c) above.
  • the starting materials of formula (4) may be prepared by the following sequence: ##STR6##
  • a lactol of formula (5) is treated with an appropriate Wittig reagent (e.g. R 3 7 P ⁇ CHOR 8 , where R 7 is as defined above and R 8 is C 1-4 alkyl) to give the vinyl ether (6).
  • the reactions may be performed as described for process (f).
  • the vinyl ether (6) is then hydrolysed to give the aldehyde (4), for example using a dilute acid such as hydrochloric acid. Acetone is a suitable solvent.
  • Lactols of the formula (7) ##STR7## may be prepared by the method described in British Patent Specification No. 2028805A, using starting materials containing the appropriate R 2 group.
  • Lactols of formula (8) ##STR8## required as starting materials may be prepared by the following sequence: ##STR9## (R h above represents a hydroxyl protecting group)
  • the norbornanone (9) is first reduced (e.g. with NaBH 4 ) to the alcohol (10) into which the R 2 group is then introduced (e.g. by reaction with R 2 L, where L is a leaving group, e.g. halogen or tosylate) to give the compound (11).
  • the protecting group (R h ) is then removed and the hydroxy group oxidised (e.g. as described for process (a)) to give the norbornanone (12).
  • the latter can then be converted into the lactol (8) by Baeyer-Villiger oxidation followed by reduction (e.g. with di-isobutyl aluminium hydride).
  • Compounds of formula (2) in which Y is in the ⁇ -configuration and the ring hydroxy group is in the ⁇ -configuration may be prepared by epimerising the corresponding compound in which the ring hydroxy group is in the ⁇ -position. This may for example be effected with triphenylphosphine in the presence of an acid (e.g. formic or benzoic acid) and (C 2 H 5 OOC.N) 2 at a low temperature. Tetrahydrofuran is a suitable solvent.
  • the acetylenes required as starting materials for process (d) may be prepared by first reacting a compound of formula (7) with a Wittig reagent (R 3 7 P ⁇ CBrR 1 ), as described above for process (f). The product is then dehydrobrominated to form the side chain acetylene group, and the ring hydroxy group then oxidised, as described for process (a).
  • a Wittig reagent R 3 7 P ⁇ CBrR 1
  • Compounds of formula (2) in which X is trans --CH ⁇ CH-- may be prepared by isomerising the corresponding cis compound.
  • the isomerisation may for example be effected by treatment with, for example, p-toluene sulphinic acid in dioxan (e.g. at reflux) or azobisisobutyronitrile and thiophenol, using for example a hydrocarbon solvent (e.g. benzene) and any suitable temperature up to reflux.
  • a hydrocarbon solvent e.g. benzene
  • Suitable starting materials of formula (16) for processes (q) and (r) above may be prepared by the following sequence: ##STR10##
  • a lactol of formula (13), in which --OR h is a protected hydroxy group is first treated with a Wittig reagent to give the vinyl ether (14), which is then converted into the aldehyde (15) by treatment with mercuric acetate. These steps are performed in the same general way as for the preparation of compounds of formula (4).
  • the compound of formula (16) may then be formed from the aldehyde (15) by the method of process (f).
  • the ether group by process (q) may be formed at an earlier stage, by etherification of the compound of formula (14).
  • This reaction may be performed by treating the starting material with a compound of the formula ZR 9 Z, where Z is a readily displaceable group (such as halo, e.g. iodo, or hydrocarbylsulphonyloxy, e.g. p-toluenesulphonyloxy) and R 9 is the appropriate divalent group (e.g. --(CH 2 ) 2 S(CH 2 ) 2 --).
  • Z is a readily displaceable group
  • R 9 is the appropriate divalent group (e.g. --(CH 2 ) 2 S(CH 2 ) 2 --).
  • the reaction may be carried out in a solvent such as acetonitrile or methanol at reflux, in the presence of a suitable base, e.g. potassium carbonate or sodium bicarbonate.
  • the amines required as starting materials for process (s) may be prepared by reduction of the corresponding azide, for example as described for process (c).
  • the azide starting materials may be prepared by methods analogous to those for preparing the compounds of formula (3), using reagents in which Y is an azido group.
  • reagents in which Y is an azido group in particular, the preparations of lactols of formula (7) in which Y is azido is described in British Patent Specification No. 2028805A.
  • modification of the group R 1 or the configuration of the double bond may be effected before the formation of the group Y by process (s).
  • the amino group may need to be protected in such transformations.
  • the ring hydroxy group will often be protected and the liberation of this (or any other hydroxy group present) will frequently be the last step in the preparation.
  • Conventional methods of protection may be used, protection in the form of dimethyl-1,1-dimethylethyl-silyloxy or tetrahydropyranyloxy groups being preferred. These groups may be removed by acid hydrolysis. Hydroxy groups may also be protected in the form of alkanoyloxy groups having up to 7 carbon atoms, e.g. acetoxy. These groups may be removed by alkaline hydrolysis.
  • enantiomeric bromohydrin (17) ##STR11## can be prepared by the method described by Newton et al in J.C.S. Chem. Comm., 1979, 908. This can then be converted into a compound of formula (1) in which the carbon atom carrying the -(CH 2 ) 2 XR 1 group is in the (R)-configuration, via the appropriate enantiomer of the lactol (7), using the methods described above.
  • Jones reagent is a solution of chromic acid and sulphuric acid in water.
  • a 2.67 M solution contains CrO 3 (26.7 g) and concentrated H 2 SO 4 (23 ml) made up to 100 ml with water. Temperatures are in °C.
  • the following abbreviations are used:
  • DIBAL--diisobutylaluminium hydride THF--tetrahydrofuran
  • DMSO--dimethylsulphoxide DMSO--dimethylsulphoxide. Chromatography was carried out using silica gel unless otherwise stated. ⁇ Dried ⁇ refers to drying with MgSO 4 . ⁇ Hyflo ⁇ is a filtration aid.
  • Zinc bromide (27 g) in dry THF (180 ml) was stirred under nitrogen at 15°-20° during the addition of p-methylphenylmagnesium bromide [prepared in ether (160 ml) from Mg (3.24 g) and 4-bromotoluene (20.52 g)]. The mixture was stirred at 20° for 2 h.
  • Nickel acetylacetonate (1.8 g) and triphenylphosphine (7.34 g) were taken into THF (40 ml) and stirred under nitrogen during the addition of DIBAL (1 M in hexane, 7 ml). After 5 min. Intermediate 72 (4.75 g) in THF (65 ml) was added followed, after a further 5 min. by the organozinc reagent. The mixture was then stirred at 22° for 30 h, whereupon saturated NH 4 Cl solution (500 ml) and EA (300 ml) were added. The aqueous solution was adjusted to pH 5-6 with 2 N hydrochloric acid and the layers separated.
  • reaction mixture was distilled at atmospheric pressure to give about 11 l of aqueous ethanol containing starting material and some product-FRACTION A. Then a steam distillation of the remaining reaction mixture gave 36 l of aqueous distillate which was salted (7.25 kg) and extracted with CH 2 Cl 2 (3 ⁇ 10 l). The CH 2 Cl 2 was distilled at atmospheric pressure through a helix filled column (93 ⁇ 5 cm) to leave a residue (about 400 ml)-FRACTION B. FRACTION A was concentrated by distilling off most of the solvent through a helix filled column (50 ⁇ 3 cm). The residue was salted and extracted into CH 2 Cl 2 -FRACTION C.
  • Aqueous NaOH solution (10 N; 200 ml) was added to a solution of the free base of Intermediate 70 (21.1 g), benzyltriethylammonium chloride (4 g) and 4-bromobenzyl bromide (27.5 g) in CH 2 Cl 2 (400 ml) and the mixture stirred vigorously for 4 h. A further portion of 4-bromobenzylbromide (9 g) was then added and stirring continued for 68 h. Water (200 ml) was added and the layers separated. The aqueous layer was extracted with EA (2 ⁇ 75 ml), washed with water, dried and evaporated to give an oil (48 g) which solidified on standing.
  • Example 1a To a solution of Example 1a (0.37 g) in dry ER (20 ml) was added piperazine (0.037 g) in dry ER (4 ml). The ER was decanted off and the residue crystallised from CH 2 Cl 2 -isopentane to give the title compound (0.2 g) m.p. 113°-114°.
  • Example 1a Aqueous 0.2 N.NaOH (2 ml) was added dropwise with stirring to a solution of Example 1a (0.25 g) in aqueous acetone (1:1), 10 ml) at room temperature until the pH reached 7.8. 7.2% w/v CaCl 2 (1 ml) was then added followed by water (10 ml) and stirring continued for 2h. The solid was filtered off, washed with water (5 ml) followed by ER (10 ml) and dried (35°/0.05 mmHg/7h) to afford the title compound (0.163 g), m.p. 132°-134°.
  • Example 1a Aqueous calcium acetate solution (0.17 g in 12 ml) was added dropwise with stirring to a solution of Example 1a) (0.6 g) and NaHCO 3 (0.106 g) in aqueous ethanol (1:1, 24 ml). The mixture was stirred for 30 min when the solid was filtered off, washed with water (10 ml) followed by ER (5 ml) and dried (45°/200 mmHg/4h) to afford the title compound (0.56 g), m.p. 135° (dec).
  • Example 1a A solution of Example 1a) (0.35 g) in ER (25 ml) was treated with a solution of N,N-dimethylpiperazine (0.084 g) in ER (5 ml) and the mixture was allowed to stand in the cold. The title compound was filtered off and dried (0.33 g), m.p. 106°-108°.
  • These may be prepared by direct compression or wet granulation.
  • the direct compression method is preferred but may not be suitable in all cases as it is dependent upon the dose level and physical characteristics of the active ingredient.
  • the active ingredient is sieved through a 250 m -6 sieve, blended with the excipients and compressed using 10.0 mm punches. Tablets of other strengths may be prepared by altering the compression weight and using punches to suit.
  • the active ingredient is sieved through a 250 m -6 sieve and blended with the lactose, starch and pregelatinised starch.
  • the mixed powders are moistened with purified water, granules are made, dried, screened and blended with the magnesium stearate.
  • the lubricated granules are compressed into tablets as described for the direct compression formulae.
  • the tablets may be film coated with suitable film forming materials, e.g. methyl cellulose or hydroxylpropyl methyl cellulose using standard techniques. Alternatively the tablets may be sugar coated.
  • suitable film forming materials e.g. methyl cellulose or hydroxylpropyl methyl cellulose using standard techniques.
  • the tablets may be sugar coated.
  • the active ingredient is sieved through a 250 m -6 sieve and blended with the other materials.
  • the mix is filled into No. 2 hard gelatin capsules using a suitable filling machine.
  • Other doses may be prepared by altering the fill weight and if necessary changing the capsule size to suit.
  • the active ingredient is micronised so that the majority of the particles are between 1 m -6 and 5 m -6 in longest dimensions and none are greater than 10 m -6 .
  • the active ingredient is then blended with the lactose and the mix is filled into No. 3 hard gelatin capsules using a suitable filling machine.
  • the aluminium monostearate is dispersed in about 90% of the fractionated coconut oil.
  • the resulting suspension is heated to 115° C. while stirring and then cooled.
  • the flavour and colour are added and the active ingredient and sucrose are suitably dispersed.
  • the suspension is made up to volume with the remaining fractionated coconut oil and mixed.
  • a sterile presentation of the active ingredient in an ampoule or vial together with an ampoule containing a suitable vehicle may be prepared by (a) filling sterile material into vials under aseptic conditions (b) freeze drying a sterile solution of the active ingredient under aseptic conditions.
  • the vehicle may be (a) Water for Injections B.P. (b) Water for Injections B.P. containing: (1) Sodium chloride to adjust the tonicity of the solution and/or (2) buffer salts or dilute acid or alkali to facilitate solution of the active ingredient.
  • the vehicle is prepared, clarified and filled into appropriate sized ampoules sealed by fusion of the glass.
  • the vehicle is sterilised by heating in an autoclave using one of the acceptable cycles.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Textile Engineering (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Shaping By String And By Release Of Stress In Plastics And The Like (AREA)
  • Artificial Filaments (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
US06/258,721 1980-04-30 1981-04-29 Aminocyclopentane alkenoic acids and esters and pharmaceutical compositions Expired - Fee Related US4342756A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB8014256 1980-04-30
GB8014256 1980-04-30
GB8100326 1981-01-07

Publications (1)

Publication Number Publication Date
US4342756A true US4342756A (en) 1982-08-03

Family

ID=26275368

Family Applications (2)

Application Number Title Priority Date Filing Date
US06/258,737 Expired - Fee Related US4327092A (en) 1980-04-30 1981-04-29 Aminocyclopentane alkenoic acids and esters and pharmaceutical formulations
US06/258,721 Expired - Fee Related US4342756A (en) 1980-04-30 1981-04-29 Aminocyclopentane alkenoic acids and esters and pharmaceutical compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US06/258,737 Expired - Fee Related US4327092A (en) 1980-04-30 1981-04-29 Aminocyclopentane alkenoic acids and esters and pharmaceutical formulations

Country Status (21)

Country Link
US (2) US4327092A (es)
JP (2) JPS5718671A (es)
KR (1) KR850000214B1 (es)
AT (1) ATA191781A (es)
AU (1) AU540147B2 (es)
BE (1) BE888645A (es)
CH (1) CH646965A5 (es)
DE (1) DE3117087A1 (es)
DK (1) DK189881A (es)
ES (2) ES8207498A1 (es)
FI (1) FI78293C (es)
FR (1) FR2481703B1 (es)
GB (1) GB2075503B (es)
IE (1) IE51241B1 (es)
IL (1) IL62734A (es)
IT (1) IT1170929B (es)
NL (1) NL8102116A (es)
NO (1) NO811470L (es)
NZ (1) NZ196966A (es)
PT (1) PT72951B (es)
SE (1) SE8102731L (es)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4410521A (en) * 1981-09-16 1983-10-18 Glaxo Group Limited Aminocyclopentane esters and pharmaceutical formulations
US4438112A (en) 1980-01-09 1984-03-20 Glaxo Group Limited Prostanoid compounds and pharmaceutical formulations
US4438111A (en) 1980-01-09 1984-03-20 Glaxo Group Limited Prostanoid compounds and pharmaceutical formulations
US4447428A (en) * 1978-07-11 1984-05-08 Glaxo Group Limited Prostanoid compounds and pharmaceutical compositions
US4482549A (en) * 1981-10-29 1984-11-13 Glaxo Group Limited Aminocyclopentane esters and pharmaceutical formulation
US4530925A (en) * 1983-03-15 1985-07-23 Glaxo Group Limited Aminocyclopentane esters and pharmaceutical formulations
US4835278A (en) * 1986-01-28 1989-05-30 Glaxo Group Limited Preparation of piperidinylcyclopentylheptenoic acid derivatives
US4847255A (en) * 1986-10-22 1989-07-11 Glaxo Group Limited Cyclopentyl ethers and their use in medicine
US4933461A (en) * 1987-06-30 1990-06-12 Glaxo Group Limited Preparation of a piperidinylcyclopentylheptenoic acid derivative
US4977163A (en) * 1981-04-29 1990-12-11 Glaxo Group Limited Aminocyclopentanol acids and esters and their preparation and pharmaceutical formulation
US5164503A (en) * 1982-10-28 1992-11-17 Glaxo Group Limited Preparation of aminocyclopentane acids
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
US20060166872A1 (en) * 2002-04-17 2006-07-27 Jabbour Henry N Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia
US20060171945A1 (en) * 2003-02-14 2006-08-03 Critchley Hilary Octavia D Ip receptor antagonists for the treatment of pathological uterine conditions
US20070004620A1 (en) * 2002-04-17 2007-01-04 Jabbour Henry N Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
US20080247954A1 (en) * 1997-09-25 2008-10-09 Pharmagene Laboratories Limited Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment
US20100035868A1 (en) * 2001-10-08 2010-02-11 Medical Research Council Methods of treatment of uterine pathological conditions
US10196343B2 (en) 2013-01-30 2019-02-05 Ecolab Usa Inc. Hydrogen sulfide scavengers
US10308886B2 (en) 2015-04-22 2019-06-04 Ecolab Usa Inc. Development of a novel high temperature stable scavenger for removal of hydrogen sulfide
US10336950B2 (en) 2016-07-29 2019-07-02 Ecolab Usa Inc. Antifouling and hydrogen sulfide scavenging compositions and methods
US10407626B2 (en) 2015-09-08 2019-09-10 Ecolab Usa Inc. Hydrocarbon soluble/dispersible hemiformals as hydrogen sulfide scavengers
US10538710B2 (en) 2017-07-13 2020-01-21 Ecolab Usa Inc. Hydrogen sulfide scavengers
US10584286B2 (en) 2015-09-08 2020-03-10 Ecolab Usa Inc. Hydrogen sulfide scavengers
US11499108B2 (en) 2019-01-23 2022-11-15 Championx Usa Inc. Complete removal of solids during hydrogen sulfide scavenging operations using a scavenger and a Michael acceptor

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201932A (en) * 1981-09-16 1985-10-11 Glaxo Group Ltd Aminocyclopentane esters(prostaglandin type compounds)and pharmaceutical compositions
GR77727B (es) * 1981-10-29 1984-09-25 Glaxo Group Ltd
AU561739B2 (en) * 1981-12-23 1987-05-14 British Technology Group Limited Prostaglandins
US4837234A (en) * 1981-12-23 1989-06-06 National Research Development Corporation Prostaglandins
GB2127406B (en) * 1982-09-16 1986-03-05 Glaxo Group Ltd Piperidinlycyclopentanolheptenoic acid salt
AU576476B2 (en) * 1982-09-16 1988-09-01 Glaxo Group Limited Piperidinylcyclopentanol heptenoic acid salt
GB2146023B (en) * 1983-09-06 1987-03-25 Glaxo Group Ltd Aminocyclopentanes and their preparation and pharmaceutical formulation
GB2167404A (en) * 1984-10-26 1986-05-29 Glaxo Group Ltd Prostanoid aminocyclopentane alkenoic acids and esters, their preparation and pharmaceutical formulation
GB2330307A (en) * 1998-02-07 1999-04-21 Glaxo Group Ltd EP4 Receptor antagonists as bone resorption inhibitors
US6861441B1 (en) 1999-08-10 2005-03-01 Smithkline Beecham Corporation Use of EP4 receptor ligands in the treatment of neuropathic pain and colon cancer
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
JP2008193940A (ja) * 2007-02-13 2008-08-28 Honda Motor Co Ltd ポリヒドロキシ酪酸精製方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182903A (en) * 1976-02-23 1980-01-08 Gruppo Lepetit S.P.A. 13-Azaprostaglandins
US4189606A (en) * 1976-02-23 1980-02-19 Gruppo Lepetit S.P.A. 13-Azaprostaglandins
US4239778A (en) * 1978-09-12 1980-12-16 The University Of Illinois Foundation Azaprostanoic acid analogs and their use as inhibitors of platelet aggregation
US4265891A (en) * 1978-07-11 1981-05-05 Glaxo Group Limited Prostanoid compounds and compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2028805B (en) * 1978-07-11 1982-11-03 Glaxo Group Ltd Prostanoid compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4182903A (en) * 1976-02-23 1980-01-08 Gruppo Lepetit S.P.A. 13-Azaprostaglandins
US4189606A (en) * 1976-02-23 1980-02-19 Gruppo Lepetit S.P.A. 13-Azaprostaglandins
US4265891A (en) * 1978-07-11 1981-05-05 Glaxo Group Limited Prostanoid compounds and compositions
US4239778A (en) * 1978-09-12 1980-12-16 The University Of Illinois Foundation Azaprostanoic acid analogs and their use as inhibitors of platelet aggregation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LeBreton, Proc. Natl. Acad. Sci. USA, 76 (1979) pp. 4097-4100. *
Orth et al, Topics in Current Chemistry, 72 (1977) pp. 51-97. *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447428A (en) * 1978-07-11 1984-05-08 Glaxo Group Limited Prostanoid compounds and pharmaceutical compositions
US4438112A (en) 1980-01-09 1984-03-20 Glaxo Group Limited Prostanoid compounds and pharmaceutical formulations
US4438111A (en) 1980-01-09 1984-03-20 Glaxo Group Limited Prostanoid compounds and pharmaceutical formulations
US4977163A (en) * 1981-04-29 1990-12-11 Glaxo Group Limited Aminocyclopentanol acids and esters and their preparation and pharmaceutical formulation
US4410521A (en) * 1981-09-16 1983-10-18 Glaxo Group Limited Aminocyclopentane esters and pharmaceutical formulations
US4482549A (en) * 1981-10-29 1984-11-13 Glaxo Group Limited Aminocyclopentane esters and pharmaceutical formulation
US5164503A (en) * 1982-10-28 1992-11-17 Glaxo Group Limited Preparation of aminocyclopentane acids
US4530925A (en) * 1983-03-15 1985-07-23 Glaxo Group Limited Aminocyclopentane esters and pharmaceutical formulations
US4835278A (en) * 1986-01-28 1989-05-30 Glaxo Group Limited Preparation of piperidinylcyclopentylheptenoic acid derivatives
US4847255A (en) * 1986-10-22 1989-07-11 Glaxo Group Limited Cyclopentyl ethers and their use in medicine
US4933461A (en) * 1987-06-30 1990-06-12 Glaxo Group Limited Preparation of a piperidinylcyclopentylheptenoic acid derivative
US8513027B2 (en) 1997-09-25 2013-08-20 Asterand Uk Acquisition Limited Method of identifying an inhibitor of the prostanoid EP4 receptor
US20080247954A1 (en) * 1997-09-25 2008-10-09 Pharmagene Laboratories Limited Methods for the treatment of primary headache disorders using prostanoid EP4 receptor antagonists, and assays for agents for such treatment
US6414006B1 (en) 1998-10-15 2002-07-02 Merck Frosst Canada & Co. Methods for inhibiting bone resorption
US6586457B2 (en) 1998-10-15 2003-07-01 Merck & Co., Inc. Methods for inhibiting bone resorption
US20100035868A1 (en) * 2001-10-08 2010-02-11 Medical Research Council Methods of treatment of uterine pathological conditions
US20060166872A1 (en) * 2002-04-17 2006-07-27 Jabbour Henry N Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia
US20070004620A1 (en) * 2002-04-17 2007-01-04 Jabbour Henry N Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
US20060171945A1 (en) * 2003-02-14 2006-08-03 Critchley Hilary Octavia D Ip receptor antagonists for the treatment of pathological uterine conditions
US10196343B2 (en) 2013-01-30 2019-02-05 Ecolab Usa Inc. Hydrogen sulfide scavengers
US10703710B2 (en) 2013-01-30 2020-07-07 Ecolab Usa Inc. Hydrogen sulfide scavengers
US11339118B2 (en) 2013-01-30 2022-05-24 Ecolab Usa Inc. Hydrogen sulfide scavengers
US10308886B2 (en) 2015-04-22 2019-06-04 Ecolab Usa Inc. Development of a novel high temperature stable scavenger for removal of hydrogen sulfide
US11085002B2 (en) 2015-04-22 2021-08-10 Championx Usa Inc. Development of a novel high temperature stable scavenger for removal of hydrogen sulfide
US10407626B2 (en) 2015-09-08 2019-09-10 Ecolab Usa Inc. Hydrocarbon soluble/dispersible hemiformals as hydrogen sulfide scavengers
US10584286B2 (en) 2015-09-08 2020-03-10 Ecolab Usa Inc. Hydrogen sulfide scavengers
US10336950B2 (en) 2016-07-29 2019-07-02 Ecolab Usa Inc. Antifouling and hydrogen sulfide scavenging compositions and methods
US10538710B2 (en) 2017-07-13 2020-01-21 Ecolab Usa Inc. Hydrogen sulfide scavengers
US11499108B2 (en) 2019-01-23 2022-11-15 Championx Usa Inc. Complete removal of solids during hydrogen sulfide scavenging operations using a scavenger and a Michael acceptor

Also Published As

Publication number Publication date
IL62734A (en) 1985-10-31
PT72951B (en) 1983-06-15
NL8102116A (nl) 1981-11-16
IE51241B1 (en) 1986-11-12
FI78293B (fi) 1989-03-31
AU6995781A (en) 1981-11-05
KR850000214B1 (ko) 1985-03-06
JPS5718671A (en) 1982-01-30
ES501740A0 (es) 1982-09-16
IL62734A0 (en) 1981-06-29
DK189881A (da) 1981-10-31
FI811350L (fi) 1981-10-31
ES8207498A1 (es) 1982-09-16
IT8148367A0 (it) 1981-04-29
DE3117087A1 (de) 1982-03-11
KR830005187A (ko) 1983-08-03
PT72951A (en) 1981-05-01
CH646965A5 (en) 1984-12-28
ES8303386A1 (es) 1983-02-01
GB2075503B (en) 1984-03-28
FI78293C (fi) 1989-07-10
ES510838A0 (es) 1983-02-01
IE810957L (en) 1981-10-30
NZ196966A (en) 1984-05-31
US4327092A (en) 1982-04-27
JPH0314028B2 (es) 1991-02-25
FR2481703B1 (fr) 1985-08-02
GB2075503A (en) 1981-11-18
JPS5882723A (ja) 1983-05-18
SE8102731L (sv) 1981-12-21
IT1170929B (it) 1987-06-03
ATA191781A (de) 1985-11-15
BE888645A (fr) 1981-10-30
NO811470L (no) 1981-11-02
AU540147B2 (en) 1984-11-01
FR2481703A1 (fr) 1981-11-06
JPH0263054B2 (es) 1990-12-27

Similar Documents

Publication Publication Date Title
US4342756A (en) Aminocyclopentane alkenoic acids and esters and pharmaceutical compositions
US4880800A (en) Aminocyclopentyl ethers and pharmaceutical formulation
GB2097397A (en) Aminocyclopentanol acids and esters as prostaglandin analogues and their preparation and pharmaceutical formulation
US4371530A (en) Aminocyclopentanone amides and pharmaceutical formulation
EP0032432B1 (en) Prostanoid compounds and their preparation and pharmaceutical formulations
US4613597A (en) Aminocyclopentanes and their preparation and pharmaceutical formulation
CA1190926A (en) Aminocyclopentane esters and their preparation and pharmaceutical formulation
US4530925A (en) Aminocyclopentane esters and pharmaceutical formulations
US4482549A (en) Aminocyclopentane esters and pharmaceutical formulation
US4977163A (en) Aminocyclopentanol acids and esters and their preparation and pharmaceutical formulation
US4410521A (en) Aminocyclopentane esters and pharmaceutical formulations
US4438112A (en) Prostanoid compounds and pharmaceutical formulations
US4438111A (en) Prostanoid compounds and pharmaceutical formulations
CA1173830A (en) Aminocyclopentane alkenoic acids and esters and their preparation and pharmaceutical formulation
US4824993A (en) Cyclopentyl ethers and their preparation and pharmaceutical formulation
GB2079281A (en) Aminocyclopentanone Amides and Their Preparation and Pharmaceutical Formulation
US5039673A (en) Aminocyclopentyl ethers and their preparation and pharmaceutical formulation
GB2167404A (en) Prostanoid aminocyclopentane alkenoic acids and esters, their preparation and pharmaceutical formulation

Legal Events

Date Code Title Description
AS Assignment

Owner name: GLAXO GROUP LIMITED, CLARGES HOUSE, 6-12 CLARGES S

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:COLLINGTON, ERIC W.;HALLETT, PETER;WALLIS, CHRISTOPHER J.;AND OTHERS;REEL/FRAME:003948/0581;SIGNING DATES FROM 19810428 TO 19810521

Owner name: GLAXO GROUP LIMITED, ENGLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:COLLINGTON, ERIC W.;HALLETT, PETER;WALLIS, CHRISTOPHER J.;AND OTHERS;SIGNING DATES FROM 19810428 TO 19810521;REEL/FRAME:003948/0581

CC Certificate of correction
MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M170); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M171); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 19940803

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362